A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France.
Fiche du document
- doi: 10.1177/03000605211021278
- issn: 0300-0605
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1177/03000605211021278
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34162264
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1473-2300
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_8FC65075C2F53
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
Infectious diseasesCiter ce document
B. Guery et al., « A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. », Serveur académique Lausannois, ID : 10.1177/03000605211021278
Métriques
Partage / Export
Résumé
To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficile infection (CDI) treated with and without fidaxomicin. This prospective, multicentre, observational study (DAFNE) enrolled hospitalised patients with CDI, including 294 patients treated with fidaxomicin (outcomes recorded over a 3-month period) and 150 patients treated with other CDI therapies during three 1-month periods. The primary endpoint was baseline and CDI characteristics of fidaxomicin-treated patients. At baseline, the fidaxomicin-treated population included immunocompromised patients (39.1%) and patients with severe (59.2%) and recurrent (36.4%) CDI. Fidaxomicin was associated with a high rate of clinical cure (92.2%) and low CDI recurrence (16.3% within 3 months). Clinical cure rates were ≥90% in patients aged ≥65 years, those receiving concomitant antibiotics and those with prior or severe CDI. There were 121/296 (40.9%) patients with adverse events (AEs), 5.4% with fidaxomicin-related AEs and 1.0% with serious fidaxomicin-related AEs. No fidaxomicin-related deaths were reported. Fidaxomicin is an effective and well-tolerated CDI treatment in a real-world setting in France, which included patients at high risk of adverse outcomes.Trial registration: Description of the use of fidaxomicin in hospitalised patients with documented Clostridium difficile infection and the management of these patients (DAFNE), NCT02214771, www.ClinicalTrials.gov.